Analysis of Anti-Glycan IgG and IgM Antibodies in Colorectal Cancer

Abstract

We propose an approach that allows simultaneous determination of the levels of M and G isotypes of antibodies to the panel of glycans using microarrays. The level of IgG antibodies to 3’-O-su-Le^a glycan detects patients with colorectal cancer with a sensitivity of 69.77% and specificity of 62.75%. The percentage of correctly classified colorectal cancer patients with the use of a combination of two markers IgM antibodies to glycans 3’-sialyl-TF and 3’-O-su-Le^a is as high as 74.23%. The levels of IgM antibodies to 3’-O-su-Le^a glycan differ significantly in patients with and without regional metastases. The levels of some of antiglycan IgM or IgG antibodies differed significantly in patients with tumors of different location and differentiation.